Introduction to in Vivo Targeting

  • Laura Chiarantini
  • Robert E. Droleskey
  • John R. DeLoach
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 326)

Abstract

In the accompanying paper, we describe a method for targeting erythrocytes in vitro.1 Antibody mediated targeting of liposomes, microspheres, drugs, and drug conjugates has been demonstrated in many instances.2–12 Moreover, selective in vitro targeting of erythrocytes to collagen-coated surfaces and in vivo to fibrin clots has been shown by others.13–15 The development of carrier systems to specifically deliver toxic drugs to cancer cells has been a continuing effort in many laboratories. The choice of carrier system is dependent to some extent on the bias of the researcher. For many years our laboratory has utilized erythrocytes to encapsulate drugs for dissemination into animal systems.16–21 The so called carrier erythrocytes offer several unique advantages over other carriers; they have a large volume, are easily prepared, are natural and under normal circumstances circulate as well as normal erythrocytes. An advantage of carrier erythrocytes is that their final destination is the reticuloendothelial system (RES). In this instance, selective in vivo targeting of drug loaded carrier erythrocyte to liver and spleen and to lesser extent lungs has been demonstrated.22 Treatment of carrier-erythrocytes by methods to shorten its in vivo life span will naturally target these erythrocytes to cells within the RES. However, anatomical limitations would seem to restrict erythrocytes to the circulatory system. Yet other routes of injection such as subcutaneous or intraperitoneal can expose erythrocytes to the lymphatic system.23,25

Keywords

Toxicity Epoxy Heparin Adenosine Syringe 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L. Chiarantini, R.D. Droleskey, M. Magnani, H. Kirch, and J.R. DeLoach, Targeting of Erythrocytes to Cytotoxic T-cells in Research in Experimental Medicine and Biology, Plenum Press, New York (1992).Google Scholar
  2. 2.
    R.J. Debs, T.D. Heath, and D. Papahadjopoulos, Targeting of anti-Thy monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration, Biochim. Biophys. Acta. 901:183 (1987).CrossRefGoogle Scholar
  3. 3.
    L. Ding, J. Samuel, G.D. MacLean, A.A. Noujaim, E. Diener, and B.M. Longenecker, Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas, Cancer Immuno Immunother. 31:105 (1990).CrossRefGoogle Scholar
  4. 4.
    Dumont, C.D. Muller, F. Schuber, and J. Bartholeyns, Antitumoral properties and reduced toxicity of LPS targeted to macrophages via normal or mannosylated liposomes, Anticancer Res. 10:155 (1990).PubMedGoogle Scholar
  5. 5.
    P.K. Gupta, Drug targeting in cancer chemotherapy: A clinical perspective, J. Pharm. Sci. 79:949 (1990).PubMedCrossRefGoogle Scholar
  6. 6.
    A. Montgomery, M. Wing, and P. Lachmann, A novel strategy for targetting CD4PPD reactive T-cells against tumour cells using PPD monoclonal antibody heteroconjugates, Clin. Exp. Immunol. 82:200 (1990).PubMedCrossRefGoogle Scholar
  7. 7.
    G. Paganelli, S. Pervez, A.G. Siccardi, G. Rowlinson, G. Deleide, F. Chiolerio, M. Malcovati, G.A. Scassellati, A.A. Epenetos, Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies, Int. J. Cancer. 45:1184 (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    A.T. Florence and G. Gregoriadis, Targeting peptides and proteins: NATO ASI, Trends Biotechnol. 9:295 (1991)PubMedCrossRefGoogle Scholar
  9. 9.
    S.M. Larson, Biologic characterization of melanoma tumors by antigen-specific targeting of radiolabeled anti-tumor antibodies, J. Nucl. Med. 32:287 (1991).PubMedGoogle Scholar
  10. 10.
    J. Liliemark, Liposomes for drug targeting in cancer chemotherapy, Eur.J. Surg.7(Suppl) 561:49 (1991).Google Scholar
  11. 11.
    J. Pappo, T. Ermak, and H. Steger, Monoclonal antibody-directed targeting of fluorescent microspheres to Peyer’s patch M cells, Immunology. 73:277 (1991).PubMedGoogle Scholar
  12. 12.
    C. Ramsden, M. Drayson, and E. Bell, Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency, Br. J. Cancer. 63:699 (1991).Google Scholar
  13. 13.
    G.P. Samokhin, M.D. Smirnov, V.R. Muzykantov, S.P. Domogatsky, and V.N. Smirnov, Red blood cell targeting to collagen-coated surfaces. FEBS Lett. 154:257 (1983).PubMedCrossRefGoogle Scholar
  14. 14.
    V.R. Muzykantov, D.V. Sakharov, M.D. Smirnov, S.P. Domogatsky, and G.P. Samokhin, Targeting of enzyme immobilized on erythrocyte membrane to collagen -coated surface, FEBS. 182:62 (1985).CrossRefGoogle Scholar
  15. 15.
    V.R. Myzykantov, D.V. Sakharov, M.D. Smirnov, G.P. Samokhin, and V.N. Smirnov, Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot. Biophys. Acta. 884:355 (1986).CrossRefGoogle Scholar
  16. 16.
    J.R. DeLoach and G. Ihler, A dialysis procedure for loading erythrocytes with enzymes and lipids, Biochim. Biophys. Acta. 496:136 (1977).CrossRefGoogle Scholar
  17. 17.
    J.R. DeLoach, S. Peters, O. Pinkard, R. Glew, and G. Ihler, Effect of glutaraldehyde treatment on enzyme-loaded erythrocytes, Biochim. Biophys. Acta 496:507 (1977).CrossRefGoogle Scholar
  18. 18.
    J.R. DeLoach and C. Barton, Circulating carrier erythrocytes: Slow-release vehicle for an antileukemic drug, cytosine arabinoside, Am. J. Vet. Res. 43:2210 (1982).PubMedGoogle Scholar
  19. 19.
    J.R. DeLoach, Encapsulation of exogenous agents in erythrocytes and the circulating survival of carrier erythrocytes, J. Appl. Biochem. 5:149 (1983).PubMedGoogle Scholar
  20. 20.
    J.R. DeLoach, Carrier erythrocytes, Med. Res. Rev. 6:487 (1986).PubMedCrossRefGoogle Scholar
  21. 21.
    M. Tonetti, B. Astroff, W. Satterfield, A. DeFlora, U. Benatti, and J.R. DeLoach, Construction and characterization of adriamycin-loaded canine red blood cells as potential slow delivery system, Biotechnol. Appl. Biochem. 12:621 (1990).Google Scholar
  22. 22.
    E. Zocchi, M. Tonetti, C. Polvani, L. Guida, U. Benatti, and A. DeFlora, Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastitic model, Proc. Natl. Acad. Sci. USA 86:2040 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    J.R. DeLoach and R.E. Droleskey, Survival of murine carrier erythrocytes injected via peritoneum. Comp. Biochem. Physiol. 84A:447 (1986).Google Scholar
  24. 24.
    J.R. DeLoach, K. Andrews, C.L. Sheffield, and K. Koths, Subcutaneous administration of [35-s]r-IL-2 in mice carrier-erythrocytes: Alteration of IL-2 pharmacokinetics, Adv. Biosci. 67:183 (1987).Google Scholar
  25. 25.
    J.R. DeLoach, K. Andrews, and C.L. Sheffield, Encapsulation of interleukin-2 in murine erythrocytes and subsequent deposition in mice receiving a subcutaneous injection, Biotechnol. Appl. Biochem. 10:183 (1988).Google Scholar
  26. 26.
    J.R. DeLoach, C.H. Tangner, and C. Barton, Hepatic pharmacokinetics of glutaraldehyde-treated methotrexate-loaded carrier erythrocytes in dogs, Res. Exp. Med. 183:167 (1983).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Laura Chiarantini
    • 1
    • 2
  • Robert E. Droleskey
    • 1
  • John R. DeLoach
    • 1
  1. 1.Food Animal Protection Research LaboratoryUSDA-ARSUSA
  2. 2.Istituto di Chimica Biologica “Giorgio Fornaini”Universita degli Studi di UrbinoUrbinoItaly

Personalised recommendations